Two-Year Prognostic Utility of Plasma p217+tau across the Alzheimer’s Continuum

被引：0
作者：
A. Feizpour
V. Doré
J. D. Doecke
Z. S. Saad
G. Triana-Baltzer
R. Slemmon
P. Maruff
N. Krishnadas
P. Bourgeat
K. Huang
C. Fowler
S. R. Rainey-Smith
A. I. Bush
L. Ward
J. Robertson
R. N. Martins
C. L. Masters
V. L. Villemagne
J. Fripp
H. C. Kolb
Christopher C. Rowe
机构：
[1] The University of Melbourne,The Florey Institute of Neuroscience and Mental Health
[2] Austin Health,Department of Molecular Imaging & Therapy
[3] CSIRO,The Australian e
[4] CSIRO,Health Research Centre
[5] Janssen Research and Development,The Australian e
[6] Cogstate Ltd,Health Research Centre
[7] Murdoch University,Neuroscience Biomarkers
[8] Edith Cowan University,Centre for Healthy Ageing, Health Futures Institute
[9] Australian Alzheimer’s Research Foundation,Department of Psychiatry
[10] University of Pittsburgh,Florey Department of Neuroscience and Mental Health
[11] The University of Melbourne,undefined
来源：
The Journal of Prevention of Alzheimer's Disease | 2023年 / 10卷
关键词：
Blood based biomarkers; cognition; clinical trials; Alzheimer’s disease; pTau;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：828 / 836
页数：8
相关论文
共 88 条
[1]  
Jack CR(2018)NIA-AA research framework: toward a biological definition of Alzheimer’s disease Alzheimers Dement 14 535-562
[2]  
Bennett DA(2022)Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility Nat Rev Neurol 18 400-418
[3]  
Blennow K(2021)Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer’s Disease Neuroimaging Initiative Mol Psychiatry 26 429-442
[4]  
Karikari TK(2018)Plasma phospho-tau181 increases with Alzheimer’s disease clinical severity and is associated with tau-and amyloid-positron emission tomography Alzheimers Dement 14 989-997
[5]  
Ashton NJ(2020)Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders Jama 324 772-781
[6]  
Brinkmalm G(2021)Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231 Alzheimers Res Ther 13 1-15
[7]  
Karikari TK(2021)Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology Acta Neuropathol 141 709-724
[8]  
Benedet AL(2020)Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia Nat Med 26 379-386
[9]  
Ashton NJ(2020)Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration Nat Med 26 387-397
[10]  
Mielke MM(2021)“Don’t Phos Over Tau”: recent developments in clinical biomarkers and therapies targeting tau phosphorylation in Alzheimer’s disease and other tauopathies Mol Neurodegener 16 1-19
123456789